GlassScriptPhysician profile
Scott D Polster
NPI 1417936048
$2,726.35
in general payments reported to CMS, 2019-2025
26 companies · $298 in 2025
The $298 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,907 · 2020: $81.35 · 2021: $61.94 · 2022: $70.03 · 2023: $56.63 · 2024: $251 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $605.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,517.35 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $286.20 | 2019-2023 | Farxiga |
| Glaxosmithkline, LLC. | $175.43 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $169.76 | 2019-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $64.19 | 2019-2024 | Zepbound, Mounjaro |
| Phathom Pharmaceuticals, INC. | $61.08 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.47 | 2025 | Jardiance |
| Astellas Pharma US INC | $50.25 | 2019 | |
| Abbott Laboratories | $48.09 | 2023-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $45.74 | 2024-2025 | Dexcom G6 Transmitter |
| Genentech USA, INC. | $33.59 | 2019 | |
| Boston Scientific Corporation | $25.92 | 2024 | Watchman Flx |
| Bayer Healthcare Pharmaceuticals INC. | $22.19 | 2024 | |
| Lundbeck LLC | $21.14 | 2025 | Rexulti |
| Shire North American Group INC | $18.93 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.76 | 2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $17.93 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.67 | 2025 | Trintellix |
| Exact Sciences Corporation | $15.69 | 2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $12.15 | 2019 | |
| Kaleo, INC. | $11.62 | 2019 | |
| Amgen INC. | $11.58 | 2020 | |
| Promius Pharma LLC | $11.35 | 2019 | |
| Allergan, INC. | $11.27 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Polster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.